Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2015
At a glance
- Drugs Sodium oligomannurarate (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Shanghai Green Valley Pharmaceutical
- 26 Jan 2015 Duration of assessment of primary end point changed from 4 weeks, 12 weeks, 24 weeks to 12 weeks only as reported by ClinicalTrials.gov record.
- 26 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.